PAFSC Approves Two New Orphan Drugs For Acute Porphyria
This article was originally published in PharmAsia News
Executive Summary
Japan’s Pharmaceutical Affairs and Food Safety Council’s Second Committee on Drugs approved the authorization of two new orphan drugs including CMIC Holdings’ Normosang for the improved treatment of seizures in patients with acute porphyria.
Japan’s Pharmaceutical Affairs and Food Safety Council’s Second Committee on Drugs approved Feb. 25 the authorization of two new orphan drugs including CMIC Holdings’ Normosang for the improved treatment of seizures in patients with acute porphyria. The new active ingredient in the 250mg intravenous infusion is hemin. (Click Here For More – Japanese Language
)
“PAFSC Second Committee Approves 2 New Orphan Drugs For Acute Porphyria Etc.” - yakuji.co.jp 03/01/2013